Showing 4851-4860 of 5957 results for "".
- Pfizer, Moderna and J&J Tout Supercharged COVID-19 Vaccine Output, Eyeing Nearly 140 Million New Doses by Marchhttps://modernod.com/news/pfizer-moderna-and-jj-tout-supercharged-covid-19-vaccine-output-eyeing-nearly-140-million-new-doses-by-march/2478909/Pfizer, Moderna, and Johnson & Johnson execs say they’re working all the angles on increasing COVID-19 vaccine production and expect to amp up weekly deliveries by tens of millions by the end of March, according to a FiercePharma
- FDA Outlines Faster Path for COVID-19 Vaccines That Tackle New Variantshttps://modernod.com/news/fda-outlines-faster-path-for-covid-19-vaccines-that-tackle-new-variants/2478898/The FDA on Monday issued new guidance confirming that drugmakers will not have to perform large-scale trials for new COVID-19 vaccines or booster shots developed to combat new variants of SARS-CoV-2. “At this time, available information suggests that the FDA-authorized vaccines remain effec
- UK Real-World Data Show COVID-19 Vaccine Linked to Lower Infection, Hospitalization Rateshttps://modernod.com/news/uk-real-world-data-show-covid-19-vaccine-linked-to-lower-infection-hospitalization-rates/2478899/Data from new analyses were released Monday shedding light on the short-term impacts of COVID-19 vaccinations in the UK. One analysis from Public Health England’s (PHE) SIREN study appears to corroborate early evidence that Pfizer and BioNTech’s vaccine BNT162b2 offers high levels of
- PYC Therapeutics Accelerates Its Pipeline of RNA Therapeutics for Ocular Diseaseshttps://modernod.com/news/pyc-therapeutics-accelerates-its-pipeline-of-rna-therapeutics-for-ocular-diseases/2478892/PYC Therapeutics announced updates to its programs and outlined its 2021-2022 corporate objectives. PYC is initially targeting inherited ocular diseases, for which it has three preclinical candidates in development. “This year we are focused on transforming PYC Therapeutics into a U.S.-bas
- Pfizer’s COVID-19 Vaccine Stimulates Lower Antibody Response Against B.1.351 Strainhttps://modernod.com/news/pfizers-covid-19-vaccine-stimulates-lower-antibody-response-against-b-1-351-strain/2478888/Preliminary findings from an in vitro study published Wednesday in the NEJM showed that Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 elicited roughly two-thirds lower levels of neutralizing antibodies against a highly transmissible SARS-CoV-2 variant that was first spotted in So
- Ophthalmic Fundraising Activity Soars in Face of Pandemichttps://modernod.com/news/ophthalmic-fundraising-activity-soars-in-face-of-pandemic/2478884/The ophthalmic market continues to expand and attract funding from investors. There were more deals in 2020 than the two previous years, and transactions totaled $8.6 billion, according to a new Market Scope report. Retina is the largest ophthalmic market sector, driven by a booming pharma
- LumiThera Completes Patient Enrollment in LIGHTSITE III Clinical Study to Treat Dry AMDhttps://modernod.com/news/lumithera-completes-patient-enrollment-in-the-lightsite-iii-clinical-study-to-treat-dry-amd/2478882/LumiThera announced it has completed enrollment in its multicenter US clinical study in non-neovascular (dry) age-related macular degeneration (AMD) patients. The randomized, multicenter study, LIGHTSITE III, enrolled the last patient at the Byers Eye Insti
- LION Eye Group Collaborates with OCLI-Spectrum Vision Partnershttps://modernod.com/news/lion-eye-group-collaborates-with-ocli-spectrum-vision-partners/2478878/New York-based LION Eye Group announces it has entered into a collaborative agreement with OCLI-Spectrum Vision Partners (OCLI) for integrated eye care. Terms of the deal were not disclosed. “The collaboration was the result of LION’s effort to engage in high quality med
- New World Medical’s Next-Generation KDB GLIDE Now Commercially Availablehttps://modernod.com/news/new-world-medicals-next-generation-kdb-glide-now-commercially-available/2478880/New World Medical announced the launch of the KDB GLIDE device for advanced excisional goniotomy treatment of glaucoma. The KDB GLIDE, which was registered with the FDA in October 2020, is now commercially available to ophthalmic surgeons across the US looking for refined, precise performance dur
- LumiThera Announces Positive Interim Data in Visual and ERG Clinical Outcomes in the ELECTROLIGHT Pilot Study in Dry AMD Patientshttps://modernod.com/news/lumithera-announces-positive-interim-data-in-visual-and-erg-clinical-outcomes-in-the-electrolight-pilot-study-in-dry-amd-patients/2478872/LumiThera announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients. A total of 23 eyes from 15 subjects with intermediate dry AMD were enrolled into the prospective clinical study and treated with PBM using the Valeda Light Delivery System (3 times per week for 3 we